Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning

Takayuki Miki*, Takahito Itoh, Daisuke Sunaga and Tetsuji Miura

Abstract
In spite of the current optimal therapy, the mortality of patients with ischemic heart disease (IHD) remains high, particularly in cases with diabetes mellitus (DM) as a co-morbidity. Myocardial infarct size is a major determinant of prognosis in IHD patients, and development of a novel strategy to limit infarction is of great clinical importance. Ischemic preconditioning (PC), postconditioning (PostC) and their mimetic agents have been shown to reduce infarct size in experiments using healthy animals. However, a variety of pharmacological agents have failed to demonstrate infarct size limitation in clinical trials. One of the possible reasons for the discrepancy between the results of animal experiments and clinical trials is that co-morbidities, including DM, modified myocardial responses to ischemia/reperfusion and to cardioprotective agents. Here we summarize observations of the effects of DM on myocardial infarct size and ischemic PC and PostC and discuss perspectives for protection of DM hearts.

Keywords: Diabetes mellitus, Infarct size, Preconditioning, Postconditioning

Introduction
Cardiovascular diseases are the leading cause of death, accounting for approximately 30% of all deaths worldwide [1]. Among the various cardiovascular diseases, acute myocardial infarction (AMI) has a high rate of mortality, and infarct size is a primary determinant of prognosis in these patients. The only established and clinically approved method to limit infarct size is restoration of coronary blood flow by percutaneous coronary interventions (PCI), thrombolytic agents or coronary bypass surgery. However, our recent review of clinical infarct size data indicated that infarct size after current reperfusion therapy was larger than 75% of the area at risk and larger than 20% of the left ventricle in one fourth of AMI patients [2]. Lack of substantial myocardial salvage in those patients cannot be simply attributable to long symptom-to-reperfusion time, and involvement of reperfusion injury [3] is also possible. Nevertheless, significant percentages of AMI patients suffer from insufficient cardiac function and have a poor prognosis even after successful restoration of coronary flow [2]. Therefore, the establishment of a novel strategy to limit the extent of infarction during ischemia/reperfusion is of great clinical importance.

As a cardioprotective strategy, ischemic preconditioning (PC) has received much attention for its potent infarct size-limiting effect since its first report by Murry et al. in 1986 [4]. Zhao et al. found that “conditioning” with repetitive ischemia/reperfusion at the time of reperfusion also affords protection and named the phenomenon ischemic postconditioning (PostC) [5]. Laboratory investigations to date have clarified outlines of the intracellular mechanisms of PC and PostC [6-9]. In addition, several agents targeting signaling relevant to PC and PostC have been shown to act as PostC mimetics [6-8]. However, clinical benefits of PC, PostC and their mimetics were not always demonstrated in clinical trials [8,10]. The discrepancy between results of animal studies and clinical trials may be explained by notable differences between animal models of AMI and AMI in humans [2,10]. First, there are species differences in regulatory mechanisms of cardiomyocytes such as contribution of sarcolemmal Ca^{2+} ATPase to overall Ca^{2+} handling. Second, the timing of administration of
the test agent was not exactly the same in the positive animal studies and negative clinical trials. Third, most of the patients with AMI were pretreated with pharmacological agents for their co-morbidities at the onset of AMI, whereas animals were untreated, except for anesthetic agents, before AMI in most of the previous studies. Pharmacological agents used for treatment of hypertension, dyslipidemia and/or diabetes mellitus (DM) potentially modify intracellular signaling relevant to cytoprotection and thus myocardial responses to PC, Post and PC mimetics. Fourth, AMI patients recruited to clinical studies were generally old and had concomitant diseases, whereas relatively young and healthy animals were used in most of the previous animal studies. Aging and co-morbidities have been shown to modify or even abrogate the infarct size-limiting effects of interventions in animal experiments [6,11] and thus possibly underlie the negative results in clinical trials.

Of morbidities that potentially compromise the protective mechanisms of the heart, DM appears primarily important to study today. The number of patients with DM has been increasing worldwide in the past two decades, and these patients are predisposed to serious cardiovascular morbidity and mortality [12]. Despite recent progress in coronary intervention strategies, DM is associated with higher mortality after AMI due to more extensive atherosclerotic lesions and also hypertension and dysfunctional left ventricle [13-15]. Interestingly, Lamblin et al. recently showed that rates of cardiovascular death and heart failure after the first AMI were higher in DM patients than in non-DM patients, though ventricular function and remodeling were comparable in the two groups [16]. The increased mortality after AMI in DM patients is unlikely to be prevented simply by improvement of glycemic control, since intensive glycemic controls failed to reduce cardiovascular events as well as mortality rate in DM patients in recent large-scale clinical trials [17-19]. Hence, we need novel strategies for protecting DM patients with coronary artery diseases from excessive myocardial ischemia/reperfusion injury. To gain an insight into a novel strategy, we thoroughly review reported effects of DM on myocardial infarct size and on protective mechanisms against infarction and discuss future perspectives in this article. Our discussion on pathophysiology and clinical approach to diabetic cardiomyopathy was recently published elsewhere [20].

Changes in myocardial susceptibility to infarction by DM

Clinical studies showed that DM increased the susceptibility of the myocardium to ischemia/reperfusion injury [21,22]. However, results of infarct size studies in diabetic animal models were contradictory (Tables 1 and 2), and the reason for the inconsistency remains unclear. Multiple mechanisms are involved in cardiomyocyte necrosis induced by ischemia/reperfusion. Depletion of intracellular ATP, intracellular overloading with Na+ and Ca2+, and increased fragility of the cell membrane are major changes during ischemia relevant to cell necrosis. Accumulating evidence supports the notion that the mitochondrial permeability transition pore (mPTP) is primed during ischemia and is opened by Ca2+ overload and burst of reactive oxygen species at the time of reperfusion, leading to irreversible loss of mitochondrial functions and cell necrosis [23]. Theoretically, modification of ischemia-induced changes or reperfusion-induced opening of the mPTP should underlie the change in myocardial susceptibility to infarction in DM hearts. However, such modification has not been understood well.

Experimental studies

Infarct size in animal models of DM was larger or smaller than or similar to, depending on reports, that in non-diabetic controls (Table 1). As shown in Table 1, there were numerous differences in experimental preparations and protocols, and a single factor cannot entirely explain the discrepancy in the effects of DM on infarct size. Duration of the diabetic state and plasma level of insulin (i.e., type 1 DM vs. type 2 DM) appear to influence myocardial tolerance against infarction. In a study by Ravinger et al. [24], infarct size after 30-min ischemia was smaller in diabetic rat hearts at 1 week after streptozotocin (STZ) injection than in controls, but this infarct size limitation was not detected 8 weeks later. Two other studies have also shown that resistance of diabetic hearts to ischemia/reperfusion injury was detectable at the early phase of DM and disappeared later [25,26]. However, enlargement of infarct size was observed as early as 8 days after STZ injection [27-29], indicating that duration of DM is not the only factor responsible for inconsistent effects of DM on infarct size.

Difference in metabolic profiles associated with DM (i.e., presence or absence of hyperinsulinemia and types of dyslipidemia) may also be responsible for different changes in infarct size in DM animals. With a few exceptions [30,31], DM models with obesity and hyperinsulinemia showed increased myocardial susceptibility to ischemia/reperfusion-induced necrosis [32-41]. In contrast, high glucose level induced simply by glucose or dextrose infusion did not affect infarct size in the majority of studies, including two recent studies [42,43] (Table 2).

Clinical studies

Increased myocardial susceptibility to infarction in DM patients was indicated by two clinical studies: infarct size
Table 1 Effect of diabetes mellitus on infarct size

| Species          | DM type | duration | Index ischemia | First author | Journal                        |
|------------------|---------|----------|---------------|--------------|--------------------------------|
|                  |         |          | min           |              |                                |
|                  |         |          | type          |              |                                |
| Infarct size enlargement |         |          |               |              |                                |
| Dog              | 2       | 75 d     | 120           | Forrat       | Cardiovasc Res 1993            |
| Rat (SD)         | 1       | 8 d      | 25            | Marfella     | Diabetologia 2002              |
| Rat (SD)         | 1       | 8 d      | 25            | Di Filippo   | Diabetes 2005                  |
| Rat (SD)         | 1       | 30 d     | 30            | Thirunavukkarasu | Free Radic Biol Med 2007 |
| Rat (Wistar)     | 1       | 2 w      | 30            | Xiao         | J Pharmacol Exp Ther 2004      |
| Rat (Zucker obese)| 2       |          | 30            | Jordan       | J Pharmacol Exp Ther 2003      |
| Rat (Zucker diabetic fatty) | 2       | (10-12 w old) | 30         | Katakam      | Am J Physiol 2007              |
| Rat (Zucker diabetic fatty) | 2       | (12-16 w old) | 30         | Yue          | Diabetes 2005                  |
| Rat (OLETF)      | 2       | (25-30 w old) | 20        | Miki         | Diabetes 2009                  |
| Rat (OLETF)      | 2       | (25-30 w old) | 20        | Hotta        | Circ Res 2010                  |
| Mice             | 1       | 8 d      | 25            | Marfella     | Diabetes 2004                  |
| Mice             | 1       | 4 w      | 60            | Liu          | Diabetes 2005                  |
| Mice (ob/ob)     | 2       | (8-10 w old) | 30         | Bouhidel     | Am J Physiol 2008              |
| Mice (ob/ob)     | 2       | (8-10 w old) | 30         | Calvert      | Diabetes 2008                  |
| Mice (ob/ob)     | 2       | (10-12 w old) | 30      | Zhu          | J Cell Mol Med 2011            |
| Mice (KK-A^{+})  | 2       | (6 w old) | 40            | Honda        | J Mol Cell Cardiol 2008        |
| Infarct size reduction |         |          |               |              |                                |
| Rabbit (NZ)      | 1       | 8 w      | 30            | Hadour       | J Mol Cell Cardiol 1998        |
| Rat (SD)         | 1       | 2 w      | 30            | Ma           | N-S Arch Pharmacol 2006        |
| Rat (Wistar)     | 2       | 11-12 m  | 30, 45        | Liu          | Circulation 1993               |
| Rat (Wistar)     | 1       | 1 w      | 30            | Ravingerová  | Mol Cell Biochem 2003          |
| Rat (Wistar)     | 1       | 4 w      | 30            | Xu           | Exp Mol Pathol 2004            |
| Rat (Wistar)     | 1       | 6 w      | 30            | Galagudza    | Neurosci Behav Physiol 2007    |
| Rat (Wistar)     | 2       | 10-12 w  | 30            | Kravchuk     | Exp Diabetes Res 2011          |
| Rat (Wistar-Kyoto)| 2       | 9 m      | 40            | Mozaffari    | Hypertension 2003              |
| Rat (Zucker diabetic fatty) | 2       | (16 w old) | 50        | Kristiansen  | Diabetologia 2004              |
| Rat (Goto-Kakizaki)| 2       | (16 w old) | 50        | Kristiansen  | Diabetologia 2004              |
| Rat (Goto-Kakizaki)| 2       | (16 w old) | 45        | Kristiansen  | Diabetologia 2011              |
| No change in infarct size |         |          |               |              |                                |
| Dog              | 1       | 3 w      | 60            | Kersten      | Am J Physiol 2000              |
| Dog              | 1       | 3 w      | 60            | Kersten      | Am J Physiol 2001              |
| Rabbit (NZ)      | 1       | 10-16 w  | 30            | Vogel        | Circ Res 1988                  |
| Rabbit (NZ)      | 1       | 4-5 w    | 60            | Niersner     | Exp Clin Endocrinol Diabetes 2002 |
| Rabbit (NZ white)| 1       | 5-6 w    | 30            | Ebel         | Pflügers Arch 2003             |
| Rat (SD)         | 1       | 6 w      | 30            | Ma           | N-S Arch Pharmacol 2006        |
| Rat (SD)         | 1       | 2 w      | 30            | Gross        | Diabetes 2007                  |
| Rat (SD)         | 1       | 4 w, 8 w | 30            | Shi-Ting     | Biomed Pharmacother 2010       |
| Rat (SD)         | 1       | 4-5 w    | 30            | Drenger      | Anesthesiology 2011            |
| Rat (SD)         | 1       | 4 w      | 30            | Okazaki      | J Mol Cell Cardiol 2011        |
| Rat (Wistar)     | 1       | 8 w      | 30            | Joyeux       | Cardiovasc Res 1999            |
| Rat (Wistar)     | 1       | 8 w      | 30            | Ravingerová  | Mol Cell Biochem 2003          |
determined by SPECT imaging after reperfusion therapy was larger by 30 ~ 70% in DM patients than in non-DM patients [21,22]. The change in myocardial tolerance to infarction is consistent with worse short- and long-term prognosis after AMI in DM patients [44,45]. Of particular relevance, Haffner et al. [46] showed that cardiovascular event risk in DM patients without prior myocardial infarction was comparable to the risk in non-diabetic patients with prior myocardial infarction. However, the untoward effects of DM on prognosis after AMI cannot be explained solely by increased myocardial vulnerability to ischemia/reperfusion injury, since the risk of heart failure and death was significantly higher in DM patients than in non-DM patients with comparable infarct sizes and left ventricular ejection fractions [47]. Myopathic changes (“diabetic cardiomyopathy”), impaired collateral recruitment, microcirculatory abnormalities, and underuse of evidence-based therapies are

| Table 1 Effect of diabetes mellitus on infarct size (Continued) |
| --- |
| Species | Duration of hyperglycemia | Blood sugar (mg/dl) | Index ischemia type | First author | Journal |
| Rat (Wistar) | 1 | 20 w | 30 regional, vivo | Xu | Exp Mol Pathol 2004 |
| Rat (Wistar) | 1 | 4 w | 25 global, vitro | Ghaboura | Basic Res Cardiol 2011 |
| Rat (Goto-Kakizaki) | 2 | 35 regional, vitro | Tsang | Diabetes 2005 |
| Rat (Goto-Kakizaki) | 2 | 35 regional, vitro | Bhamra | Basic Res Cardiol 2008 |
| Rat (Goto-Kakizaki) | 2 (12 w old) | 35 regional, vivo | Bulhak | Am J Physiol 2009 |
| Rat (Goto-Kakizaki) | 2 | 30 regional, vivo | Matsumoto | Cardiovasc Drug Ther 2009 |
| Mice | 1 | 2 w | 30 global, vitro | Przyklenk | Antioxid Redox Signal 2011 |
| Mice (ob/ob) | 2 (12-14 w old) | 30 global, vitro | Przyklenk | Antioxid Redox Signal 2011 |

SD, Sprague–Dawley; NZ, New Zealand; OLETF, Otsuka Long-Evans-Tokushima fatty; d, days; w, weeks.

| Table 2 Effect of hyperglycemia on infarct size |
| --- |
| Species | Duration of hyperglycemia | Blood sugar (mg/dl) | Index ischemia type | First author | Journal |
| Dog before I | before ischemia | 585 vs. 71 | 60 regional, vivo | Kersten | Am J Physiol 1998 |
| Rabbit (NZ white) throughout | before ischemia | 594 vs. 99 | 30 regional, vitro | Wong | J Diabetes Complications 2011 |
| Rat (SD) during I | during ischemia | 324 vs 85 | 30 regional, vivo | Su | Am J Physiol 2007 |
| | No change in infarct size |
| Dog before I | before ischemia | 310 vs. 71 | 60 regional, vivo | Kersten | Am J Physiol 1998 |
| Dog before I | before ischemia | 310 vs. 75 | 60 regional, vivo | Kersten | Am J Physiol 2001 |
| Dog before I | before ischemia | 316, 579 vs. 78 | 60 regional, vivo | Kehl | Anesthesiology 2002 |
| Dog before I | before ischemia | 307 vs 83 | 60 regional, vivo | Gu | Anesthesiology 2008 |
| Rabbit (NZ white) before and during I | before and during ischemia | 660 vs. 185 | 30 regional, vivo | Ebel | Pflugers Arch 2003 |
| Rabbit (NZ white) before I | before ischemia | 257 vs 124 | 30 regional, vivo | Amour | Anesthesiology 2010 |
| Rabbit (NZ white) before and during I | before and during ischemia | 338 vs 142 | 40 regional, vivo | Raphael | J Cardiovasc Pharmacol 2010 |
| Rat (SD) before and during I | before and during ischemia | 360 vs 112 | 30 regional, vivo | Ichinomiya | Cardiovasc Diabetol 2012 |
| Rat (Wistar) before and during I | >400 vs. 121 | 25 regional, vivo | Weber | Eur J Pharmacol 2008 |
| Rat (Wistar) before and during I | 459 vs 128 | 25 regional, vivo | Huhn | Br J Anaesth 2008 |
| Rat (Wistar) before and during I | 355 vs 89 | 30 regional, vivo | Matsumoto | Cardiovasc Diabetol 2012 |
| | Metabolic syndrome |
| Infarct size enlargement |
| Rat (Wistar) Western diet for 16 w | before ischemia | 95 vs 87 | 40 regional, vitro | du Toit | Am J Physiol 2008 |
| | No change in infarct size |
| Rat (SD) high fat diet for 13 w | before ischemia | 160 vs 144 | 45 regional, vivo | Thim | Clin Sci (Lond) 2006 |
| Rat (WOKW) (28 w old) | before ischemia | 105 vs ? | 30 regional, vivo | Wagner | J Cardiovasc Pharmacol 2008 |

NZ New Zealand, SD Sprague–Dawley, WOKW Wistar-Ottawa-Karlsburg W; before I before ischemia, during I during ischemia, w weeks.
possible explanations, in addition to increased susceptibility to infarction, for detrimental prognosis after AMI in DM patients.

**Defects in intracellular protective signaling in DM hearts**

DM is one of the co-morbidities that potentially modify myocardial response to protective interventions, including PC and PostC. A number of studies have been carried out to determine the efficacy of ischemic PC and PostC for protecting the myocardium in animal models of DM (Tables 3 and 4) and diabetic patients (Table 5). The majority of those studies showed that DM interferes with protective mechanisms of cardioprotective interventions. Myocardial protection by PC and PostC is achieved by activation of multiple protective signaling pathways that appear to converge to inhibit mPTP opening upon reperfusion via phosphorylation of glycogen synthase kinase-3β (GSK-3β) at Ser9 [6,8,9], and DM-induced defects in the protective signaling may be different depending on the model and/or phase of DM.

**Experimental studies**

With a few exceptions, previous studies demonstrated that cardioprotection achieved by ischemic PC or PostC is impaired in DM: the infarct size-limiting effect was lost or required extra cycles of ischemia/reperfusion in experimental diabetes (Table 3). Tsang et al. [48] reported that one, two and three cycles of ischemic PC significantly reduced infarct size in normal rats; however, three cycles of ischemic PC were required to limit infarct size in diabetic Goto-Kakizaki rats. Their findings suggested that the threshold for PC protection is increased in the diabetic myocardium. Liu et al. [49] were the first to examine the effects of DM on PC and they reported preservation of PC protection in STZ-induced DM. However, since they used a PC protocol with multiple cycles of ischemia/reperfusion only, the change in the threshold for inducing PC protection might have been missed in their study. In fact, impairment of PC by DM has been observed in multiple species (rats, rabbits and dogs) and different models of DM (STZ-induced type 1 DM and genetic models of type 2 DM) [30,37,50-54]. Mimetics of ischemic PC and PostC (diazoxide, erythropoietin, [D-Ala², D-Leu⁵]-enkephalin acetate [DADLE] and isoflurane) were also ineffective for limitation of infarct size in DM hearts [33,34,36,48,57-59], confirming that DM impairs intracellular signaling mechanisms relevant to myocardial protection.

Several steps in cytoprotective signaling have been found to be disrupted by DM in the heart. Blocked or attenuated signaling via phosphoinositide-3 kinase (PI3K)-Akt, extracellular signal-regulated kinase (ERK) and/or signal transducer and activator of transcription-3 (STAT3) pathways was detected in association with loss or reduced efficiency of PC in protection against infarction [31,33,34,36,48,57-59]. Our recent studies have shown that phosphorylation of Jak2, being upstream of PI3K-Akt signaling, is inhibited by enhanced calcineurin activity and that phosphorylation of GSK-3β by ERK is lost by an endoplasmic reticulum stress-dependent mechanism in OLETF, a rat model of obese type 2 DM [33,34]. Furthermore, protein level of active GSK-3β, a pro-necrotic and pro-apoptotic kinase, was increased in mitochondria, leading to reduction in the threshold for mPTP opening in response to Ca²⁺ overload [34]. On the other hand, a protective mechanism downstream of GSK-3β phosphorylation appears to be intact in diabetic hearts, since direct pharmacological inhibitors of GSK-3β limited infarct size in diabetic hearts as in nondiabetic animals [33,34,54,57,58].

An important and clinically relevant issue is whether hyperglycemia per se is responsible for disruption of protective signaling in PC and PostC. Acute hyperglycemia induced by dextrose infusion attenuated infarct size limitation by ischemic PC, a mitochondrial ATP-sensitive K⁺ channel opener and anesthetic agents (Table 4). These results indicate a primary role of hyperglycemia in impairment of protective signaling. Interestingly, Przyklenk et al. [31] reported that the cardioprotective effect of ischemic PostC was re-established in STZ-induced diabetic mice by pancreas islet cell transplantation. Transplantation of islet cells in diabetic mice normalized both blood glucose level and free fatty acid level and cellular signaling, such as ERK phosphorylation, activated by ischemic PostC. Since dyslipidemia was also shown to attenuate the infarct size-limiting effect of ischemic PC [60,61], restoration of myocardial response to PostC in the diabetic heart by islet cell transplantation might be achieved by normalization of both plasma glucose level and lipid profile. Nevertheless, circumstantial evidence in animal experiments supports the notion that normalization of the metabolic profile restores protective signaling mechanisms in the DM heart.

**Clinical studies on PC**

PC protection in human hearts has been demonstrated by results of in vitro experiments using human ventricular myocytes [62] and atrial trabeculae [63] and by detailed analyses of myocardial responses in patients with naturally occurring ischemic syndromes [64,65]. Since ischemic PC and PC-like phenomena in human hearts have been recently reviewed elsewhere [7,65], we briefly summarize the results that are relevant to the effects of DM on ischemic PC. As for PC-like effects of preinfarct angina, different groups reported that pre-
| Species | DM type | duration | PC stimuli | First author | Journal |
|---------|---------|----------|------------|--------------|---------|
| **Preserved protection** | | | | | |
| **PC** | | | | | |
| Rat (SD) | 1 | 4 w | 3x 5I5R | Shi-Ting | Biomed Pharmacother 2010 |
| Rat (Wistar) | 2 | 11-12 m | 3x 5I5R | Liu | Circulation 1993 |
| Rat (Wistar) | 1 | 6 w | LiCl 20 mM, IND 1 μM, SB 3 μM | Yadav | Mol Cell Biochem 2010 |
| Rat (Zucker diabetic fatty) | 2 | (10-12 w old) | Rosiglitazone 3 mg/kg for 1 week | Yue | Diabetes 2005 |
| Rat (OLETF) | 2 | (25-30 w old) | SB 1.2 mg/kg | Miki | Diabetes 2009 |
| Rat (Goto-Kakizaki) | 2 | | 3x 5I10R | Tsang | Diabetes 2005 |
| Rat (Goto-Kakizaki) | 2 | (12 w old) | WY 1 mg/kg | Bulhak | Am J Physiol 2009 |
| Rat (Goto-Kakizaki) | 2 | | Olprinone 10 μg/kg | Matsumoto | Cardiovasc Drug Ther 2009 |
| Mice (ob/ob) | 2 | (8-10 w old) | Metformin 125 μg/kg | Calvert | Diabetes 2008 |
| Mice (KK-A1) | 2 | (6 w old) | Pioglitazone 25 mg/kg for 2 week | Honda | J Mol Cell Cardiol 2008 |
| **PostC** | | | | | |
| Rat (SD) | 1 | 2 w | SB 0.6 mg/kg | Gross | Diabetes 2007 |
| Rat (Wistar) | 1 | 4 w | SB 3 μM | Ghoboura | Basic Res Cardiol 2011 |
| Rat (OLETF) | 2 | (25-30 w old) | BIO 0.08 mg/kg | Hotta | Circ Res 2010 |
| Rat (Goto-Kakizaki) | 2 | | Metformin 50 μM | Bhamra | Basic Res Cardiol 2008 |
| Mice (ob/ob) | 2 | (8-10 w old) | Metformin 125 μg/kg | Calvert | Diabetes 2008 |
| **Impaired protection** | | | | | |
| **PC** | | | | | |
| Dog | 1 | 3 w | 4x 5I5R | Kersten | Am J Physiol 2000 |
| Dog | 1 | 3 w | Diazoxide 2.5 mg/kg | Kersten | Am J Physiol 2001 |
| Rabbit (NZ) | 1 | 4-5 w | 3x 2I2R | Nieszner | Exp Clin Endocrinol Diabetes 2002 |
| Rat (SD) | 1 | 8 w | 3x 5I5R | Wang | Biomedicine Aging Pathol 2011 |
| Rat (Wistar) | 1 | 6 w | 5I5R | Galagudza | Neurosci Behav Physiol 2007 |
| Rat (Wistar) | 1 | 6 w | 4x 5I5R | Yadav | Mol Cell Biochem 2010 |
| Rat (Wistar) | 2 | 10-12 w | Metformin 200 mg/kg for 3 days | Krahchuk | Exp Diabetes Res 2011 |
| Rat (Zucker obese) | 2 | (10-12 w old) | 5I5R, Diazoxide 10 mg/kg | Katakarn | Am J Physiol 2007 |
| Rat (Zucker diabetic fatty) | 2 | (16 w old) | 4x 2I3R | Kristiansen | Diabetologia 2004 |
| Rat (OLETF) | 2 | (25-30 w old) | EPO 5000 U/kg | Miki | Diabetes 2009 |
| Rat (OLETF) | 2 | (25-30 w old) | EPO 5000 U/kg, DADLE 1 mg/kg | Hotta | Circ Res 2010 |
| Rat (Goto-Kakizaki) | 2 | (16 w old) | 4x 2I3R | Kristiansen | Diabetologia 2004 |
| Rat (Goto-Kakizaki) | 2 | | 5I10R, 2x 5I10R | Tsang | Diabetes 2005 |
| Rat (Goto-Kakizaki) | 2 | (16-18 w old) | EPO 5000 U/kg | Miki | Diabetes 2009 |
| Rat (Goto-Kakizaki) | 2 | | Isoflurane 1.0% | Matsumoto | Cardiovasc Drug Ther 2009 |
| **PostC** | | | | | |
| Rat (SD) | 1 | 2 w | Morphine 0.3 mg/kg | Gross | Diabetes 2007 |
| Rat (SD) | 1 | 4-5 w | 3x 20iR20sI, sevoflurane 1.0 MAC | Drenger | Anesthesiology 2011 |
| Rat (Wistar) | 1 | 4 w | Darbopoetin alpha 5 μg/kg | Ghoboura | Basic Res Cardiol 2011 |
| Mice | 1 | 2 w | 3x 10sR10sI, 6x 10sR10sI | Przyklenk | Antioxid Redox Signal 2011 |
| Mice (ob/ob) | 2 | (8-10 w old) | 6x 10sR10sI | Bouchard | Am J Physiol 2008 |
| Mice (ob/ob) | 2 | (12-14 w old) | 3x 10sR10sI, 6x 10sR10sI | Przyklenk | Antioxid Redox Signal 2011 |
| Mice (ob/ob) | 2 | (10-12 w old) | 6x 10sR10sI | Zhu | J Cell Mol Med 2011 |
infarct angina was associated with smaller infarct size determined by creatine kinase (CK) release, improved left ventricular function and reduced mortality [64,66]. Furthermore, in overall analysis of AMI patients, angina before AMI was associated with better long-term prognosis [67,68]. However, in patients with DM, beneficial effects of pre-infarct angina were not detected [69]. Ishihara et al. [69] showed that CK release and recovery of cardiac function and in-hospital mortality after AMI were similar in DM patients with and without pre-infarct angina. DM-induced impairment of ischemic PC protection in human hearts has also been indicated by studies in which myocardial injury was assessed during angioplasty [70] and during a treadmill exercise test [71] by use of electrocardiography. Direct evidence for diabetes-induced loss of ischemic PC protection in the human myocardium was provided by an in vitro experiment using atrial trabeculae obtained at open heart surgery. CK release and contractile dysfunction after hypoxia/reoxygenation in vitro was

Table 3 Effect of diabetes mellitus on cardioprotection by pre- and post-conditioning (Continued)

| Species       | Duration of Blood sugar | PC stimuli | First author | Journal          |
|---------------|-------------------------|------------|--------------|------------------|
| Mice (KK-A')  | 2 (6 w old)             | Pioglitazone 25 mg/kg | Honda        | J Mol Cell Cardiol 2008 |

Late PC

| Rabbit (NZ white) | 1-5-6 w | SI24R   | Miki et al. Cardiovascular Diabetology 2012, 11:67 |

IND indirubin-3 monooxime (a GSK-3β inhibitor), SB SB216763 (a GSK-3β inhibitor), WY 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (a PPAR-α agonist), BDO 6-bromo-indirubin-3'-oxime (a GSK3β inhibitor), EPO erythropoietin, DADLE [D-Ala2, D-Leu5]-enkephalin acetate (a δ-opioid receptor agonist), SISR 5-min ischemia/5-min reperfusion, SI24R 5-min ischemia/24-hour reperfusion, 10sR10sI 10-second reperfusion/10-second ischemia, MAC minimal alveolar concentration, w weeks, m months.

Table 4 Effect of hyperglycemia on cardioprotection by pre- and post-conditioning

| Species        | Duration of Blood sugar | PC stimuli | First author | Journal          |
|----------------|-------------------------|------------|--------------|------------------|
| Hyperglycemia  |                         |            |              |                  |
| Preserved protection |                   |            |              |                  |
| PC             |                         |            |              |                  |
| Dog            | before I                | 397        | Diazoxide 5.0 mg/kg | Kersten        | Am J Physiol 2001 |
| Dog            | before I                | 291        | Isoflurane 1.0 MAC   | Kehl           | Anesthesiology 2002 |
| Rat (SD)       | before and during I     | 360        | Fasudil 0.5 mg/kg    | Ichinomiya     | Cardiovasc Diabetol 2012 |
| Rat (Wistar)   | before and during I     | 446        | Sevoflurane 1.0 MAC + CysA 5 mg/kg | Huhn       | Br J Anaesth 2008 |
| Rat (Wistar)   | before and during I     | 343, 447   | MIL 30 μg/kg, LEVO 100 μg/kg | Matsumoto     | Cardiovasc Diabetol 2012 |
| Impaired protection |                   |            |              |                  |
| PC             |                         |            |              |                  |
| Dog            | before I                | 296        | 4x SISR      | Kersten        | Am J Physiol 1998 |
| Dog            | before I                | 329        | Diazoxide 2.5 mg/kg | Kersten        | Am J Physiol 2001 |
| Dog            | before I                | 581, 558   | Isoflurane 0.5, 1.0 MAC | Kehl       | Anesthesiology 2002 |
| Dog            | before I                | 293        | 4x SISR      | Gu             | Anesthesiology 2008 |
| Rabbit (NZ white) | before I        | 281        | Isoflurane 1.0 MAC   | Amour          | Anesthesiology 2010 |
| Rat (Wistar)   | before I or during I    | >400       | Desflurane 1.0 MAC   | Weber          | Eur J Pharmacol 2008 |
| PostC          |                         |            |              |                  |
| Rabbit (NZ white) | before and during I  | 353        | Isoflurane 1.0 MAC   | Raphael        | J Cardiovasc Pharmacol 2010 |
| Rat (SD)       | before and during I     | 360        | Diazoxide 10 mg/kg, Fasudil 0.15 mg/kg | Ichinomiya   | Cardiovasc Diabetol 2012 |
| Rat (Wistar)   | before and during I     | 445, 441   | Sevoflurane 1.0 MAC + CysA 5 mg/kg | Huhn        | Br J Anaesth 2008 |
| Metabolic syndrome |                   |            |              |                  |
| Impaired protection |                   |            |              |                  |
| PostC          |                         |            |              |                  |
| Rat (WOKW)     | (28 w old)              | 105        | 3x 30sR30sR   | Wagner          | J Cardiovasc Pharmacol 2008 |

NZ New Zealand, SD Sprague-Dawley, WOKW Wistar-Ottawa-Karlsburg W, before I before ischemia, during I during ischemia, MAC minimal alveolar concentration, CysA cyclosporine A, MIL milrinone, LEVO levosimendan, SISR 5-min ischemia/5-min reperfusion, 30sR30s 30-second reperfusion/30-second ischemia.
suggest that larger numbers of balloon inflations are associated with greater protection in patients with AMI. However, an appropriate algorithm of PostC stimulus to maximally protect the human myocardium has not been established. In addition, protection by PostC in animal models of AMI is attenuated with aging and presence of co-morbidities, such as DM, hypertension and hypercholesterolemia [6,11]. Although characteristics of patients, such as age and prevalence of DM, seem to be similar in the human studies (Table 5), difference in durations of the co-morbidities might have been involved in the different outcomes. Nevertheless, the effect of DM on protection afforded by PostC has not been specifically examined in clinical studies.

The effects of pharmacological PostC (i.e., administration of pharmacological agents at reperfusion) on myocardial injury have been examined in a number of clinical trials. Results of the trials are a mixture of positive and negative results, and the reason for the discrepancy remains unknown [82-92]. Adenosine infusion limited infarct size, but neither the death rate during 6-month follow-up nor the rate of rehospitalization for heart failure were reduced by the adenosine treatment [82,84]. A post hoc analysis suggested that only patients with early reperfusion therapy received clinical benefits of adenosine, such as a reduction in death or heart failure [85]. In the J-WIND trial [86], the effects of nicorandil and ANP on infarct size in different study arms were examined. Administration of nicorandil failed to significantly limit infarct size, though recombinant ANP infusion was shown to induce a small but significant reduction in infarct size. The results of studies on the effect of erythropoietin administered at reperfusion were discrepant [87-92]. Taken together, there are a few promising agents for

### Table 5 Effect of ischemic postconditioning in patients with acute myocardial infarction

| First author | % of DM | Age | Protocol | Results | Enzyme release | Infarct size |
|--------------|---------|-----|----------|---------|---------------|-------------|
| **Ischemic PostC** | | | | | | |
| Staat | 20 vs. 13 | 58 vs. 56 | 4x 60sR/I | Improved | N/A | Reduced (peak, AUC) | N/A |
| Laskey | N/A | 58 vs. 58 | 2x 90sR/I | Improved | N/A | No change (peak) | N/A |
| Ma | 38 vs. 45 | 64 vs. 64 | 3x 30sR/I | N/A | Improved WMSI | Reduced (peak) | N/A |
| Yang | 26 vs. 28 | 59 vs. 63 | 3x 30sR/I | No change | No change | Reduced (AUC) | Reduced (SPECT, 1w) |
| Thibault | 12 vs. 10 | 56 vs. 56 | 4x 60sR/I | N/A | Improved EF, WMSI | Reduced (AUC) | Reduced (SPECT, 6m) |
| Laskey | 38 vs. 42 | 60 vs. 58 | 2x 90sR/I | Improved | No change | Reduced (peak) | N/A |
| Xue | 21 vs. 29 | 54 vs. 62 | 4x 60sR/I | Improved | Improved EF, WMSI | Reduced (peak, AUC) | Reduced (SPECT, 1w) |
| Lønborg | 7 vs. 7 | 61 vs. 62 | 4x 30sR/I | No change | No change | No change | Reduced (CMR, 3m) |
| Sörensson | 25 vs. 17 | 63 vs. 62 | 4x 60sR/I | N/A | No change *1 | No change (AUC) | No change (CMR, 1w) *1 |
| Freixa | 23 vs. 17 | 59 vs. 60 | 4x 60sR/I | Improved | No change | No change (peak) | No change (CMR, 1w & 6m) |
| Tarantini | 18 vs. 3 | 60 vs. 60 | 4x 60sR/I | No change | No change | No change (AUC) | No change (CMR, 1m) |

*DM diabetes mellitus, MBG myocardial blush grade, CF coronary flow, WMSI wall motion score index, EF ejection fraction, AUC area under the curve, MACE major adverse cardiac events, SPECT single photon emission computed tomography, CMR cardiovascular magnetic resonance, w week, m month; *1 Improved by postconditioning with large area at risk.

Clinical studies on PostC

In contrast to PC, PostC or administration of its mimetic at the time of reperfusion is clinically feasible. In 2005, Staat et al. [73] translated for the first time the concept of ischemic PostC into the clinical setting. PostC with four cycles of 1-min inflation and 1-min deflation before full reperfusion successfully reduced CK release in a small and selected cohort of patients with AMI. Efficacy of ischemic PostC in patients with AMI was subsequently confirmed in a number of small-scale studies, using as endpoints cardiac biomarkers, ECG ST-segment resolution, and anatomic infarct size (Table 5). However, three recent studies failed to show protection by ischemic PostC in terms of CK and troponin release, LV function or infarct size that was determined by delayed enhancement magnetic resonance imaging (MRI) [74-76]. The reasons for the discrepant results remain uncertain, but there are some possibilities: differences in the protocols of ischemic PostC, presence of co-morbidities and use of different pharmacological agents for the co-morbidities.

In the PostC protocol, duration from reperfusion to the first re-occlusion and number of re-occlusions have been shown to influence the infarct size-limiting effects of PostC in animal models of AMI [77-79]. Retrospective analyses by Darling et al. [80] and Wang et al. [81] suggest that larger numbers of balloon inflations–deflations were associated with greater protection in patients with AMI. However, an appropriate algorithm of PostC stimulus to maximally protect the human myocardium has not been established. In addition, protection by PostC in animal models of AMI is attenuated with aging and presence of co-morbidities, such as DM, hypertension and hypercholesterolemia [6,11]. Although characteristics of patients, such as age and prevalence of DM, seem to be similar in the human studies (Table 5), difference in durations of the co-morbidities might have been involved in the different outcomes. Nevertheless, the effect of DM on protection afforded by PostC has not been specifically examined in clinical studies.

The effects of pharmacological PostC (i.e., administration of pharmacological agents at reperfusion) on myocardial injury have been examined in a number of clinical trials. Results of the trials are a mixture of positive and negative results, and the reason for the discrepancy remains unknown [82-92]. Adenosine infusion limited infarct size, but neither the death rate during 6-month follow-up nor the rate of rehospitalization for heart failure were reduced by the adenosine treatment [82,84]. A post hoc analysis suggested that only patients with early reperfusion therapy received clinical benefits of adenosine, such as a reduction in death or heart failure [85]. In the J-WIND trial [86], the effects of nicorandil and ANP on infarct size in different study arms were examined. Administration of nicorandil failed to significantly limit infarct size, though recombinant ANP infusion was shown to induce a small but significant reduction in infarct size. The results of studies on the effect of erythropoietin administered at reperfusion were discrepant [87-92]. Taken together, there are a few promising agents for
infarct size limitation in AMI patients, but none of their effects has been unequivocally demonstrated to be sufficient for improving prognosis.

Effects of anti-diabetic medications on AMI in diabetic patients

Possible adverse effects of sulfonylureas on cardiac events in DM patients have been debated for decades, and recent studies have indicated that cardiovascular risk was significantly higher in DM patients treated with sulfonylureas than in those who received metformin monotherapy [93,94]. Sulphonylureas have been shown to inhibit protection of PC and PostC by blocking the ATP-sensitive K⁺ channel (K\(\text{ATP}\) channel) in cardiomyocytes, raising concern that such actions of sulphonylureas may be detrimental at the time of AMI in DM patients. However, the effects on PC and PostC are actually not uniform across sulfonylureas. Glibenclamide, a non-specific blocker of the K\(\text{ATP}\) channel, abrogated the infarct size-limiting effect of PC and PostC in non-diabetic animals [6,7,95]. In contrast, glimepiride, a second-generation sulfonylurea, did not block the protective effect of PC in the animal myocardium or human myocardium [96,97], presumably because this agent has few cardiac actions [98]. In addition, glimepiride was shown to have a PostC-mimetic action by activation of PI3K/Akt in the rabbit myocardium [99]. However, the effects of sulfonylureas on PC in diabetes have been tested in only a few studies [51,96], since PC and PostC failed to limit infarction in most of the DM models. Interestingly, Nieszner et al. [51] reported that infarct-sparing effect of PC in alloxan-treated diabetic rabbits was restored by pretreatment with a low dose, but not a high dose, of glibenclamide. The mechanism by which glibenclamide restored myocardial response to PC in the DM rabbit is unclear. However, beneficial effects of glycemic control, possibly on PI3K/Akt signaling, might have overwhelmed the effect of partial inhibition of cardiac K\(\text{ATP}\) channels when an appropriate dose of glibenclamide was selected.

Metformin is an insulin-sensitizing agent that reduces hepatic glucose output and increases the uptake of glucose in peripheral tissues, including the skeletal muscle. In non-diabetic animals, metformin reduced infarct size by activation of AMP-activated protein kinase and/or Akt [95]. However, whether metformin is additive to ischemic PC or PostC has not been examined. Infarct size-limiting effect of metformin in diabetic animals was controversial: there are two positive reports [40,100] and one negative report [101]. Thiazolidinediones (pioglitazone, rosiglitazone) administered before ischemia reduced infarct size in both normal and diabetic animals [39,41,95]. However, the impact of the cardioprotective effect of thiazolidinediones on clinical outcome is unclear, since the effects of pioglitazone and rosiglitazone on risk of cardiovascular events appear discrepant [102].

In the past few years, growing evidence has demonstrated cardiovascular effects of incretin-based therapy using glucagon-like peptide-1 (GLP-1) receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4) [95,103-105]. However, the effects of GLP-1 receptor agonists or DPP-4 inhibitors on ischemia/reperfusion injury have not been examined in diabetic animals except for a study by Huisamen et al. [106] They reported that enlargement of infarct size in obese pre-diabetic rats was reduced by treatment with a DPP-4 inhibitor for 4 weeks [106]. Further investigation is necessary for clarifying the effects of GLP-1 analogues and DPP-4 inhibitors on intracellular protective signaling and its modification by DM, though there are a number of on-going large-scale clinical trials to test the effects of incretin-based therapy on cardiovascular outcomes [107].

Conclusions and perspectives

DM potentially increases myocardial susceptibility to ischemia/reperfusion injury, though it cannot be explained by chronic hyperglycemia alone. DM also modifies myocardial responses to ischemic and pharmacological PC and PostC by disruption of intracellular signaling responsible for enhancement of resistance to cell death. These alterations in the diabetic heart appear to underlie the poor prognosis of DM patients after AMI. In addition, a defect of the protective mechanisms caused by aging, DM and possibly other co-morbidities is one of possible reasons why infarct size-limiting effects of agents in animal studies could not have been translated into AMI patients.

Analyses of modifications of cytoprotective signaling by DM, heart failure, dyslipidemia and hypertension generally showed that defects in the signaling by the pathological factors are upstream of a step of GSK-3β phosphorylation and mPTP regulation [6,9]. Hence, a reasonable approach to protect the heart in DM patients is manipulation of protective mechanisms at the level of GSK-3β or mPTP. Blockade of mPTP opening by cyclosporine A at the time of reperfusion is one such approach, and its effect was first examined in 58 AMI patients [108]. Infarct size determined by MRI at 5 days after AMI was significantly limited by cyclosporine A and the beneficial effects persisted until 6 month after AMI [109]. The results are very promising and support the feasibility of a strategy for cardioprotection targeting the mPTP. However, how DM modifies the mPTP regulation and how we can suppress opening of the mPTP at the time of reperfusion need to be further investigated for devising a novel therapy for cardioprotection in DM patients.
Competing interests
Tahf has received research funding from Daiichi-Sankyo, Japan, Eisai, Japan, and Pfizer, Japan. TI and DS have no conflicts of interest or financial ties to disclose. TeM has received research funding from Takeda Pharmaceuticals, Japan, Novartis, Japan, Chugai Pharmaceutical, Japan, and Astellas Pharma, Japan.

Authors' contributions
Tahf collected and analyzed the data in sequence, drafted and correspond the manuscript. TI and DS contributed to collection and analysis of the data. TeM contributed to analysis and interpretation of data and revision. All authors have read and approved the final manuscript.

Received: 4 June 2012 Accepted: 6 June 2012
Published: 13 June 2012

References
1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 2012, 125(1):e2–e220.

2. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 2008, 103(6):501–513.

3. Yellon DM, Hauseney DJ. Myocardial reperfusion injury. N Engl J Med 2007, 357(11):1211–1235.

4. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74(5):1124–1136.

5. Zhao QZ, Condra J, Kalkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic preconditioning during postconditioning: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003, 285(2):H579–H588.

6. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007, 59(4):418–458.

7. Yellon DM, Downey M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003, 83(4):1113–1151.

8. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J. Yellon DM, Schulz R. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010, 87(3):406–423.

9. Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol 2011, 301(5):H1723–H1741.

10. Bull R, Becker L, Gross G, Mentzer R, Balsch D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004, 95(2):125–134.

11. Przyklenk K. Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrum. Drugs Aging 2011, 28(5):331–343.

12. Danai G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Farzadfar JK, Farzadfar F, Khang YH, Stevens GA, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378(9785):31–40.

13. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, Mehran R, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008, 51(7):708–715.

14. Cubbon RM, Wheatcroft SB, Grant PJ, Gale CP, Barth JH, Sapford RJ, Aljan R, Kearney MT, Hall AS. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 2007, 28(5):540–545.

15. Hofmann A, Lindback J, Ryden L, Wallentin L, Stenestrand U. Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart (British Cardiac Society 2007, 93(12):1577–1583.

16. Lambinis N, Fertin M, de Groote P, Bauters C. Cardiac remodeling and heart failure after a first anterior myocardial infarction in patients with diabetes mellitus. J Cardiovasc Med (Hagenton) 2012, 13(8):353–359.

17. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560–2572.

18. Gerstein HC, Miller ME, Byrington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Gemuth S, Tailang-Begi F, Grim RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545–2559.

19. Duckworth W, Abaria C, Mortiz T, Reda D, Emanuelne N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129–139.

20. Miki T, Yudia S, Kouzu H, Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 2012, Epub ahead of print.

21. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Querishi M, Kaynchly A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, et al. Comparison of myocardial reperfusion protection in patients undergoing percutaneous coronary intervention in ST-segment elevation myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol 2007, 100(2):206–210.

22. Alegria JR, Miller TD, Gibbons RJ, Yi QL, Yusuf S. A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans 2010, 38(4):841–860.

23. Ravingerova T, Neckar J, Kolar F. Contradictory effects of short- and long-term hyperglycemias on ischemic injury of myocardium via intracellular signaling pathway. Exp Mol Pathol 2004, 76(3):157–65.

24. Ma G, Al-Shabrawiy M, Johnson JA, Datar R, Tawfik HE, Guo D, Caldwell RB, Caldwell RW. Protection against myocardial ischemia/reperfusion injury by short-term diabetes: enhancement of VEGF formation, capillary density, and activation of cell survival signaling. Naunyn Schmiedebergs Arch Pharmacol 2006, 370(3):415–427.

25. Marfella R, D’Amico M, Di Filippo C, Piegari E, Nappo F, Esposito K, Berrino L, Rossori F, Giugliano D. Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia 2002, 45(1):117–1181.

26. Marfella R, Di Filippo C, Esposito K, Nappo F, Piegari E, Cuzzocrea S, Berrino L, Rossori F, Giugliano D, D’Amico M. Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes 2004, 53(2):454–462.

27. Di Filippo C, Marfella R, Giugliano D, Piegari E, Petronella P, Giugliano D, Rossori F, D’Amico M. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes 2005, 54(3):803–810.

28. Krishnan SB, Lofgren B, Strotten NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, Flyvbjerg A. Ischaemic preconditioning does
not protect the heart in obese and lean animal models of type 2 diabetes. Diabetes 2004; 47(10):1716–21.

31. Przybylo K, Maynard M, Greiner DL, Whitaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal 2011, 14(5):781–790.

32. Jordan JE, Smindle SA, Tulbert CD, Busija DW, Miller AW: Fructose-fed rats are protected against ischemia/reperfusion injury. J Pharmacol Exp Ther 2003, 307(3):1007–1011.

33. Hotta H, Miura T, Miki T, Togashi N, Maeda T, Kim SJ, Tanno M, Yano T, Kuno A, Itoh T, et al: Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circ Res 2010, 106(1):129–132.

34. Miki T, Miura T, Hotta H, Tanno M, Yano T, Sato T, Terashima Y, Takada A, Ishikawa S, Shimamoto K: Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocyte protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes 2009, 58(12):2863–2872.

35. La Bonte LR, Davis-Gorman G, Stahl GL, McDonagh PF: Complement inhibition reduces myocardial injury in the type 2 diabetic heart following ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2008, 294(3):H1282–H1292.

36. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B: Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in db/db mice. Am J Physiol Heart Circ Physiol 2008, 295(4):H1530–H1536.

37. Katahira PN, Jordan JE, Snipes JA, Tulbert CD, Miller AW, Busija DW: Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Physiol 2007, 292(2):R902–R926.

38. Zhu SG, Xi L, Kukreja RC: Type 2 diabetic Obese db/db mice are refractory to myocardial ischemic postconditioning In Vivo: potential role for Hsp20, F(1) -ATPase delta, and EchO. J Cell Mol Med 2012, 16(9):950–958.

39. Yue TL, Bao W, Gu JL, Gui J, Tao L, Ma XL, Ohlstein EH, Jucker BM: Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54(2):554–562.

40. Calvert JW, Gundewar S, Jha S, Greer JJ, Besterman WH, Tian R, Deij JF: Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008, 57(3):769–705.

41. Honda T, Kakita K, Tsujita K, Hayasaki T, Matsukawa M, Fuchigami S, Sugiyama S, Sasaki A, Ogawa H, Takeya M: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol 2008, 44(1):915–926.

42. Ichinomiya T, Cho S, Higashijima U, Matsumoto S, Maekawa T, Sumikawa K: High-dose fadul preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channels. Cardiovasc Diabetol 2012, 11:28.

43. Matsumoto S, Cho S, Tosaka S, Higashijima U, Maekawa T, Hara T, Sumikawa K: Hyperglycemia raises the threshold of levisomendin- but not milrinone-induced postconditioning in rats. Cardiovasc Diabetol 2012, 11:4.

44. Zuanetti G, Latini R, Magoni AP, Santoro L, Franzosi MG: Influence of diabetes on mortality in acute myocardial infarction: data from the GRACE Registry. J Am Coll Cardiol 2006, 47(4):1218–1224.

45. Rong WA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Ischemia-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Research Cardiol 2012, 107(2):173–169.

46. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG: Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000, 278(4):H1218–H1224.

47. Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai MZ: Influence of the diabetic heart and that of different atherosclerotic lesions on the size of myocardial infarction with and without ischemic preconditioning in rabbits. Exp Clin Endocrinol Diabetes 2002, 110(2):212–218.

48. Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai MZ: Influence of the diabetic myocardium to ischemia and the efficacy of ischemic preconditioning in experimental diabetes mellitus. Neurosci Behav Physiol 2007, 37(5):489–493.

49. Yadav HN, Singh M, Sharma PL: Involvement of GSK-3beta in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart. Mol Cell Biochem 2010, 343(1–2):275–81.

50. Kenet JR, Montgomery MW, Ghassemi T, Gross E, Pager PS, Waller DC: Diabetes abolishes ischemic preconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Mol Cell Biochem 2008, 314(1):19–28.
104. Yin M, Sille H, Meisner M, van Gilst WH, de Boer RA: Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 2011, 10:85.

105. Chinda K, Palee S, Surinkaw S, Phornphutkul M, Chattipakorn N: Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol 2012, 160:302. Epub ahead of print.

106. Huisamen B, Genis A, Marais E, Lochner A: Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011, 25(1):13–20.

107. Ussher JR, Drucker DJ: Cardiovascular biology of the incretin system. Endocr Rev 2012, 33(2):187–215.

108. Piet C, Croisille P, Staat P, Thibault H, Ricoufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, et al: Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008, 359(5):473–481.

109. Mewton N, Croisille P, Gahide G, Ricoufol G, Bonnefoy E, Sanchez I, Cung TT, Sportouch C, Angoulvant D, Finet G, et al: Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 2010, 55(12):1200–1205.

doi:10.1186/1475-2840-11-67
Cite this article as: Miki et al: Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovascular Diabetology 2012 11:67

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit